[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355377-105":59,"doc-detail-355377-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","treatment-of-hrd-positive-elderly-ovarian-cancer-patient-a-case-report","Treatment of HRD-positive elderly ovarian cancer patient - a case report","","Standard care for advanced ovarian cancer usually combines cytoreductive surgery with platinum-taxane chemotherapy, followed by maintenance in responsive patients. Frailty and comorbidities in elderly individuals often reduce surgical feasibility, necessitate chemotherapy dose reductions, and limit maintenance continuation, worsening prognosis. Poly(ADP-ribose) polymerase inhibitors (PARPi) are central for homologous recombination deficiency (HRD)-positive disease. This case report describes an 89-year-old with high-grade serous ovarian carcinoma treated with a first-line, surgery- and chemotherapy-intolerant regimen combining fluzoparib with megestrol acetate (MA) based on BRCA2 mutation and HRD positivity, showing marked tumor reduction without progression or grade ≥3 adverse events during follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-of-hrd-positive-elderly-ovarian-cancer-patient-a-case-report/355377/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-of-hrd-positive-elderly-ovarian-cancer-patient-a-case-report/355377.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What standard treatment approach is used for advanced ovarian cancer, and why is it difficult for elderly patients?","Question",{"text":112,"@type":113},"Standard management typically uses cytoreductive surgery followed by six cycles of platinum-based chemotherapy, then maintenance therapy for responders. In elderly patients, frailty and comorbidities can impair surgical outcomes, require chemotherapy dose reductions, and reduce the ability to continue maintenance therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment regimen was used in the reported 89-year-old patient?",{"text":117,"@type":113},"An innovative first-line primary regimen combining fluzoparib with megestrol acetate (MA) was initiated because the patient was intolerant to surgery and chemotherapy, guided by BRCA2 mutation and HRD-positive status.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcomes observed during follow-up?",{"text":121,"@type":113},"Imaging showed significant tumor reduction, with no disease progression and no grade ≥3 adverse events reported throughout the follow-up period.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355377,1790185175,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","352  \nCase report  \nTreatment of HRD-positive elderly ovarian cancer patient: a case report  \nYuxin Jiang* , Qijun Yi* , Yueer Wang, Chen Li and Haiyan Liu  \nThe standard treatment for advanced ovarian cancer follows a comprehensive ‘surgery-chemotherapymaintenance therapy’ mode, typically involving initial cytoreductive surgery aiming for R0 resection, six cycles of platinum-based chemotherapy, followed by maintenance therapy for those who have responded well to the treatment. However, frailty and high incidence of comorbidities in elderly patients often compromise surgical outcomes, necessitate chemotherapy dose reductions, and limit maintenance therapy continuation, resulting in a poor prognosis. Poly (Adenosine diphosphate (ADP)-ribose) polymerase inhibitors (PARPi) have revolutionized the management strategy of homologous recombination deficiency (HRD)-positive patients as a groundbreaking advancement in first  \nline maintenance therapy. Fluzoparib, the domestically developed PARPi in China, has demonstrated significant efficacy in BRCA-mutated ovarian cancer. In the field of supportive care, megestrol acetate (MA) is recommended as the first-line preferred therapeutic agent for cancerrelated anorexia by major guidelines, though its role in first-line ovarian cancer therapy remains unexplored, and evidence for its combination with PARPi is lacking. This article reported a case of an 89-year-old female patient with high-grade serous ovarian carcinoma. Due to  \nintolerance to surgery and chemotherapy, an innovative first-line primary treatment regimen combining fluzoparib with MA was initiated based on BRCA2 mutation and HRD-positive status. Imaging assessments revealed significant tumor reduction without disease progression or grade ≥3 adverse events observed throughout follow-up. This case highlights the potential of combining PARPi and hormone therapy as a ‘chemotherapy-free’ precision treatment model for elderly and HRD-positive ovarian cancer patients, offering a promising strategy to balance efficacy and tolerability in a population traditionally underserved by conventional regimens. Anti-Cancer Drugs 37: 352–357 Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.  \nAnti-Cancer Drugs 2026, 37:352–357  \nKeywords: advanced age, case reports, megestrol acetate, ovarian cancer, PARP inhibitor  \nDepartment of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China  \nCorrespondence to Haiyan Liu, MD, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, Shandong Province, China  \nTel: +86 13001770627; e-mail: [fylhy1998@163.com](fylhy1998@163.com)  \n*Yuxin Jiang and Qijun Yi contributed equally to the writing of this article. Received 15 September 2025 Revised form accepted 15 September 2025.  \nIntroduction  \nOvarian cancer ranks as the third most common gynecological malignancy worldwide. It is a leading cause of gynecological cancer-related mortality due to its highgrade malignancy, aggressive invasiveness, and a propensity for recurrence. Due to the insidious onset of the disease and the lack of effective early screening strategies, about 80% of patients are diagnosed with advanced ovarian cancer (stage III–IV). With treatment, the 5-year overall survival (OS) rate for advanced ovarian cancer is between 10 and 40%[1]. The standard initial treatment for advanced ovarian cancer involves cytoreductive surgery combined with platinum-taxane chemotherapy. Epidemiological analyses reveal that [2], over half of newly diagnosed ovarian cancer cases occur in women aged 65 years or older, with a mortality rate exceeding  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without pe","cbCaimQJTTKpiqPQ","https://ap.wps.com/l/cbCaimQJTTKpiqPQ","pdf",1043676,"English","# Introduction\n## Background and rationale for PARP inhibitors and supportive care\n## Study focus and proposed chemotherapy-free approach","[{\"question\":\"What standard treatment approach is used for advanced ovarian cancer, and why is it difficult for elderly patients?\",\"answer\":\"Standard management typically uses cytoreductive surgery followed by six cycles of platinum-based chemotherapy, then maintenance therapy for responders. In elderly patients, frailty and comorbidities can impair surgical outcomes, require chemotherapy dose reductions, and reduce the ability to continue maintenance therapy.\"},{\"question\":\"What treatment regimen was used in the reported 89-year-old patient?\",\"answer\":\"An innovative first-line primary regimen combining fluzoparib with megestrol acetate (MA) was initiated because the patient was intolerant to surgery and chemotherapy, guided by BRCA2 mutation and HRD-positive status.\"},{\"question\":\"What were the main outcomes observed during follow-up?\",\"answer\":\"Imaging showed significant tumor reduction, with no disease progression and no grade ≥3 adverse events reported throughout the follow-up period.\"}]","Treatment of HRD-positive elderly ovarian cancer patient - a case report | PDF",1790118224,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39f81fd0b1ca88afcd54aecd0d541511.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2439bd00fa79d4a27015a84bcc54e78d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44acb586d6d1439f5a21ed7c7355fb66.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4d188e250fab03ed83bc1bca01e5b90.webp",980,1306]